Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 128 full-time employees. The company went IPO on 2019-06-19. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The firm is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
Follow-Up Questions
Who is the CEO of Stoke Therapeutics Inc?
Mr. Ian Smith is the Chief Executive Officer of Stoke Therapeutics Inc, joining the firm since 2023.
What is the price performance of STOK stock?
The current price of STOK is $21.95, it has decreased 13.37% in the last trading day.
What are the primary business themes or industries for Stoke Therapeutics Inc?
Stoke Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Stoke Therapeutics Inc market cap?
Stoke Therapeutics Inc's current market cap is $1.2B
Is Stoke Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 11 analysts have made analyst ratings for Stoke Therapeutics Inc, including 6 strong buy, 9 buy, 2 hold, 0 sell, and 6 strong sell
